रैंकिंग पर वापस जाएं

iRhythm Technologies, Inc. (IRTC)

Fair Value
HealthcareMedical DevicesUnited States

Fundamental

43

मूल्य

$113.66

मार्केट कैप

$3.75B

भाग 1 · कंपनी का मूल्य कितना है

अवलोकन

iRhythm Holdings, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology that provides ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. The company offers Zio ambulatory cardiac monitoring services, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. It also provides Zio Monitor System, a prescription-only remote electrocardiogram (ECG) monitoring system consisting a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days; Zio XT System, a prescription-only remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and Zio ECG Utilization Software System, which supports the capture and analysis of ECG data. In addition, the company offers Zio AT System, a prescription-only remote ECG monitoring system, which consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days, as well as incorporates the Zio AT wireless gateway to provide connectivity between the patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with BioIS to develop and commercialize pulse oximetry, accelerometry, and trending non-invasive blood pressure technologies for use within ambulatory cardiac monitoring products and services. The company was formerly known as iRhythm Technologies, Inc. and changed its name to iRhythm Holdings, Inc. in January 2026. iRhythm Holdings, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

No editorial profile for this company yet

Direct competitors

Who this company fights with for the same customers

Compare

Generated on 18 सितंबर 2026 with claude-haiku-4-5 — shared with all users

P/E: 17.7Score: 78Market cap: $63.93B

Its Preventice Solutions arm, acquired for $925 million, is the closest challenger to Zio in long-term continuous ECG patch monitoring in the United States.

P/E: —Score: 51Market cap: $12.14B

Baxter owns Bardy Diagnostics, whose Carnation ambulatory monitor patch is prescribed for the same arrhythmia work-ups that Zio is used for.

P/E: 15.7Score: 61Market cap: $30.20B

GE HealthCare supplies the traditional 24-to-48-hour Holter monitors that hospitals and clinics can choose instead of sending a patient home with a Zio patch.

Koninklijke Philips N.V. (Royal Philips)PHG

Through BioTelemetry, which it bought for $2.8 billion, Philips sells the wearable ECG patches and mobile cardiac telemetry services that compete directly with iRhythm's Zio for the same cardiologists and the same insurance reimbursement.

Medtronic plcMDT

Medtronic's LINQ family of insertable cardiac monitors targets the same patients under investigation for atrial fibrillation and unexplained fainting, competing for the diagnostic referral before a Zio is ever prescribed.

VitalConnect, Inc.Not tracked

This private US company sells the VitalPatch, a disposable ECG patch with AI arrhythmia detection sold to the same cardiology practices that buy Zio.

बैलेंस शीट और तरलता

राजस्व

$825M

पिछले 12 महीने (30/6/2026 तक)

शुद्ध आय

$-14M

पिछले 12 महीने (30/6/2026 तक)

Free Cash Flow

$35M

कुल इक्विटी

$153M

कुल देनदारियाँ

$867M

Current Ratio

3.85

Interest Coverage

1.89

Debt/EBITDA

-

Earnings Per Share

राजस्व और शुद्ध आय

Free Cash Flow

आय विवरण

ऐतिहासिक विवरण

समय के साथ मार्जिन

समय के साथ ऋण

ऋण कितना भारी है

वृद्धि तालिका

वृद्धि — राजस्व

Fair Value अनुमान

सामान्य मामलाउचित मूल्यांकित

Fair Value

$104.37

वर्तमान मूल्य

$113.66

Margin of Safety

-8.9%

Fair Value सीमा

$67.84 - $140.89

इस्तेमाल किए गए valuation methods के बीच का फैलाव, कोई सांख्यिकीय रूप से calibrated confidence interval नहीं।

अनुमान विधियाँ

विश्लेषकों का लक्ष्य मूल्य:$176.14
डिस्काउंटेड कैश फ्लो (DCF):$14.64
आय गुणक (P/E):इसकी गणना के लिए पर्याप्त डेटा नहीं
Graham वृद्धि फॉर्मूला:इसकी गणना के लिए पर्याप्त डेटा नहीं
अर्निंग पावर वैल्यू (EPV):इसकी गणना के लिए पर्याप्त डेटा नहीं
उचित P/B:इसकी गणना के लिए पर्याप्त डेटा नहीं
लाभांश डिस्काउंट (Gordon):इसकी गणना के लिए पर्याप्त डेटा नहीं
P/FFO, परिचालन से प्राप्त निधि:इसकी गणना के लिए पर्याप्त डेटा नहीं
मध्य-चक्र आय:इसकी गणना के लिए पर्याप्त डेटा नहीं
राजस्व गुणक:$98.85
विश्लेषक सहमति:दृढ़ खरीदें (20B / 1H / 0S)
अंतिम Earnings सरप्राइज़:+12988.89%

मूल्यांकन मेट्रिक्स

P/E Ratio

-

ROE

-29.2%

P/B Ratio

20.14

P/FCF

96.12

Gross Margin

71.5%

ROIC

-2.2%

लाभप्रदता Radar

मूल्य सृजन (प्रतिस्पर्धी बढ़त)

ROIC

-2.2%

WACC

10.5%

ROIC − WACC

-12.7 pp

ROIC पूंजी की लागत से कम है — कंपनी निवेशित हर डॉलर पर मूल्य नष्ट कर रही है।

Fundamental विश्लेषण मानदंड

पास (12)

  • EPS shows upward trend
  • Price CAGR 14.06%
  • Gross Margin 71.5%
  • Positive Free Cash Flow
  • Current Ratio
  • Interest Coverage
  • Low reliance on intangibles
  • Revenue Growth 5Y 23.0%
  • Analyst Consensus 95% Buy
  • Earnings Surprise avg 3463.2%
  • Net Margin Trend -1.7% vs -14.1%
  • Piotroski F-Score 6/9

फेल (10)

  • ROIC -2.2%
  • P/FCF 96.12
  • P/B Ratio 20.14
  • Debt/Equity ratio
  • Operating Margin -3.0%
  • CapEx intensity
  • Return on Tangible Assets
  • DCF valuation (Overvalued)
  • ROE -9.0%
  • Share Dilution 2.7%

अनुपलब्ध (5)

  • Dividend Payout NaN%
  • Debt/EBITDA
  • Price below Graham Number
  • PEG Ratio (need PE > 0 and growth > 0)
  • Earnings Quality (OCF/Net Income)

Piotroski F-Score

6/9

मिश्रित संकेत: कुछ क्षेत्रों पर ध्यान देना आवश्यक

score
criteria

Earnings गुणवत्ता

-

निम्न गुणवत्ता: accounting की जांच करें

शेयर Dilution

2.7%

नए शेयर जारी कर रही है, स्वामित्व को कम कर रही है

संस्थागत होल्डिंग

प्रशासन

कार्यकारी टीम

नामपदआयु
Mr. Quentin S. BlackfordPresident, CEO & Director46
Mr. Daniel G. WilsonCFO & Principal Financial Officer43
Dr. Minang P. Turakhia M.D., M.S.Chief Medical & Scientific Officer and Executive VP of Advanced Technologies51
Mr. Patrick Michael Murphy J.D.Chief Business & Legal Officer46
Mr. Chad M. PattersonChief Commercial and Product Officer43
Mr. Mervin SmithExecutive Vice President of Business Operations50
Mr. Marc RosenbaumSenior VP of Finance & Chief Accounting Officer52
Mr. Brian LawrenceExecutive VP & CTO55
Ms. Lisa PecoraSenior Vice President of Finance & Investor Relations-
Mr. Sean Clinton FreemanExecutive Vice President of Strategy & Corporate Development49

Audit जोखिम

9

बोर्ड जोखिम

5

मुआवजा जोखिम

3

शेयरधारक अधिकार जोखिम

7

भाग 2 · कीमत और खरीदने का समय

यह हिस्सा यह नहीं बताता कि कंपनी अच्छी है या नहीं: यह तय करने में मदद करता है कि उसे कब खरीदें, जब फंडामेंटल आपको आश्वस्त कर चुके हों। इसमें: तकनीकी विश्लेषण, संभावना, ऐतिहासिक गिरावट, गामा एक्सपोज़र।

दस्तावेज़

  • वार्षिक रिपोर्ट (10-K)

    कंपनी के कारोबार, वित्तीय नतीजों और जोखिमों का वार्षिक सिंहावलोकन।

    दाखिल तिथि: 2026-02-19

    दस्तावेज़ देखें
  • तिमाही रिपोर्ट (10-Q)

    पिछले तीन महीनों के वित्तीय प्रदर्शन का अपडेट।

    दाखिल तिथि: 2026-08-06

    दस्तावेज़ देखें
  • विशेष रिपोर्ट (8-K)

    किसी बड़ी घटना, जैसे नेतृत्व में बदलाव या बड़ी घोषणा, की सूचना।

    दाखिल तिथि: 2026-09-22

    दस्तावेज़ देखें

via SEC EDGAR

आय का इतिहास

via SEC EDGAR

Latest News

Recent headlines for IRTC, sourced from Markets Gazette.

  • 3d agoPOSITIVE
    JP Morgan forecasts a 20x revenue increase for this AI stock

    JP Morgan has significantly boosted its outlook for US-listed iRhythm Technologies Inc. (IRTC), forecasting a remarkable 20-fold increase in the company's revenue by 2030. This optimistic projection is underpinned by the escalating demand for computing power and a concurrent rise in the pricing power of 'neocloud' companies like iRhythm. In a September note, the bank upgraded IRTC from 'Underweight' to 'Overweight', signaling strong conviction in its future growth trajectory. Investors should monitor iRhythm's ability to capitalize on this burgeoning market, as the forecast suggests substantial upside potential.

  • 6/16/2026NEGATIVE
    iRhythm Investigates Cyber Incident After Hackers Claim Access To Sensitive Data

    iRhythm Technologies is investigating a cybersecurity incident where hackers claim to have accessed sensitive patient and proprietary data. The breach reportedly occurred via third-party applications. While the company states it does not foresee a material impact on its operations or finances, any data breach involving patient information can lead to regulatory scrutiny, reputational damage, and potential legal liabilities. Investors will monitor the situation closely for any further developments or undisclosed consequences that could affect the company's long-term prospects and stock valuation.

via Markets Gazette

Disclaimer

यह प्लेटफ़ॉर्म केवल शैक्षिक उद्देश्यों के लिए है। यह कोई वित्तीय, निवेश, या ट्रेडिंग सलाह नहीं देता। सभी स्कोर, मूल्यांकन, और संकेत सार्वजनिक रूप से उपलब्ध डेटा के स्वचालित विश्लेषण पर आधारित हैं जो अधूरे या गलत हो सकते हैं। निवेश निर्णय लेने से पहले हमेशा अपना शोध करें और एक योग्य वित्तीय सलाहकार से परामर्श लें।

निर्मित द्वारा CODEPRESS s.r.l.